Multiple Myeloma | Clinical

Application for Subcutaneous Daratumumab Regimen Submitted to FDA, EMA Seeking Approval in R/R Myeloma

November 12, 2020

Regulatory applications have been submitted to the FDA and European Medicines Agency seeking approval of a subcutaneous form of daratumumab in combination with pomalidomide and dexamethasone as treatment of patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.

Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?

October 29, 2020

Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.

MYC Status Relevant to Risk Stratification in Newly Diagnosed Multiple Myeloma

October 29, 2020

In evaluating MYC rearrangement and its correlation with disease burden and prognostics in newly diagnosed multiple myeloma, a group of Mayo Clinic investigators found that the alteration is associated with high disease burden and independently prognosticates adverse outcomes in patients.

Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients

October 11, 2020

During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.

Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma

October 11, 2020

In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.

FDA Grants Priority Review to Ide-Cel for Relapsed/Refractory Multiple Myeloma

September 22, 2020

The FDA granted a Priority Review designation to idecabtagene vicleucel as treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.